FDA lifts import ban on Chinese API to prevent shortages

Generics/General | Posted 18/03/2016 post-comment0 Post your comment

The US Food and Drug Administration (FDA) has lifted its ban on one of the active pharmaceutical ingredients (APIs) from China-based Zhejiang Hisun Pharmaceutical (Hisun) due to a ‘critical drug shortage concern’.

Drug shortages V13C22

On 18 February 2016, FDA revised its import alert notification to allow Hisun to import cancer drug daunorubicin. 

Hisun is still under an import alert, initiated in September 2015, which means that all other API products from the company are banned entry to the US. The import ban came three months before a warning letter, which cited the company for failure to prevent unauthorized access or changes to data, and failure to provide adequate controls to prevent manipulation and omission of data. 

The originator product is marketed in the US as Cerubidine (daunorubicin hydrochloride). The product is an anticancer (antineoplastic or cytotoxic) chemotherapy drug and is used to treat acute myelogenous leukaemia (AML) and acute lymphoblastic leukaemia (ALL). It belongs to a class of drugs known as anthracyclines and works by slowing or stopping the growth of cancer cells. 

FDA announcement states that ‘only the API Daunorubicin HCl (NDC 58623-0046) for the Daunorubicin liposomal application (NDA# 50704) has a critical drug shortage concern’ and should be ‘excluded from (DWPE) [Detention without Physical Examination]. FDA adds that ‘shipments destined to any other manufacturer should be detained as per the Import Alert’, stating as the reason problems with Good Manufacturing Practices (GMP). 

Drug shortages remain a major problem for FDA. Most drug shortages involve generic, sterile injectables; in 2011, these accounted for 73% of all reported drug shortages [1]. 

The action for daunorubicin has been taken temporarily, according to an FDA spokeswoman, in order to prevent a possible future shortage. The drug has been in short supply in the past – a situation that was resolved in 2015. 

Related articles
FDA announces two actions to combat drug shortages

FDA approves new suppliers to alleviate cancer drug shortages

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Drug shortages linked to quality control costs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Mar 18]. Available from: www.gabionline.net/Pharma-News/Drug-shortages-linked-to-quality-control-costs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: US FDA

comment icon Comments (0)
Post your comment
Related content
FDA reaches 100 generic approvals
53 MD002445
Generics/General Posted 12/11/2021
New five-year medicines agreements in Australia
24-AA011041
Generics/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Generics/General Posted 23/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010